{"nctId":"NCT01554397","briefTitle":"Study With Intensity Modulated Radiation Therapy With Cisplatin to Treat Stage I-IVA Cervical Cancer","startDateStruct":{"date":"2011-10-13","type":"ACTUAL"},"conditions":["Cervical Cancer"],"count":101,"armGroups":[{"label":"IMRT with concurrent cisplatin 40 mg/m2","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Cisplatin","Radiation: IMRT"]},{"label":"PET-guided Bone Marrow-Sparing IMRT","type":"EXPERIMENTAL","interventionNames":["Radiation: PET-guided Bone Marrow-Sparing Intensity Modulated Radiation Therapy (IMRT)","Drug: Cisplatin"]}],"interventions":[{"name":"PET-guided Bone Marrow-Sparing Intensity Modulated Radiation Therapy (IMRT)","otherNames":["PET-guided Bone Marrow-Sparing IMRT"]},{"name":"Cisplatin","otherNames":["Platinol"]},{"name":"IMRT","otherNames":["Intensity Modulated Radiation Therapy"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Biopsy-proven, invasive squamous cell carcinoma, adenocarcinoma, or adenosquamous carcinoma of the cervix\n* Biopsy result positive for carcinoma within 60 days prior to registration\n* FIGO clinical stage I-IVA disease, based on standard diagnostic workup, including:History/physical examination and/or Examination under anesthesia (if indicated)\n* If the patient is status post hysterectomy, one or more of the following conditions must be present: positive lymph nodes, positive margins, parametrial invasion, or non-radical surgery (i.e., simple hysterectomy).\n* If the patient is inoperable, one or more of the following conditions must be present: clinical stage IB2-IVA, positive lymph nodes on nodal sampling or frozen section, and/or parametrial invasion\n* Within 42 days prior to registration, the patient must have any of the following, if clinically indicated: examination under anesthesia, cystoscopy, sigmoidoscopy, rigid proctoscopy, or colonoscopy.\n* X-ray (PA and lateral), CT scan, or PET/CT scan of the chest within 42 days prior to registration;\n* CT scan, MRI, or PET/CT of the pelvis within 42 days prior to registration;\n* Karnofsky Performance Status 60-100\n* Absolute neutrophil count (ANC) ≥ 1500 cells/mm3; Platelets ≥ 100,000 cells/mm3; Hemoglobin ≥ 10.0 g/dl (Note: The use of transfusion or other intervention to achieve Hgb ≥ 10.0 g/dl is acceptable); Creatinine clearance ≥ 50 mg/dl; Bilirubin \\< 1.5 mg/dl; WBC ≥ 3,000/μl; ALT/AST \\< 3 x ULN; INR ≤ 1.5\n* Negative serum pregnancy test for women of child-bearing potential\n\nExclusion Criteria:\n\n* Prior invasive malignancy (except non-melanomatous skin cancer), unless disease free for a minimum of 3 years;\n* Prior systemic chemotherapy within the past three years\n* Prior radiotherapy to the pelvis or abdomen that would result in overlap of radiation therapy fields;\n* Para-aortic, inguinal, or gross (unresected) pelvic nodal metastasis. Gross pelvic nodal metastasis is defined as either: Radiographic evidence of nodal metastasis on CT or MRI (node having short axis diameter \\> 1 cm)OR Radiographic evidence of nodal metastasis on diagnostic FDG-PET or PET/CT scan (abnormally increased FDG uptake as determined and documented by the radiologist)OR Biopsy-proven metastasis (e.g. needle biopsy) in undissected node\n* Distant metastasis\n* Unstable angina and/or congestive heart failure requiring hospitalization within the past 6 months\n* Hepatic insufficiency resulting in clinical jaundice and/or coagulation defects\n* Uncontrolled diabetes, defined as diabetes mellitus, which in the opinion of any of the patient's physicians requires an immediate change in management;\n* Uncompensated heart disease or uncontrolled high blood pressure\n* Acquired Immune Deficiency Syndrome (AIDS) based upon current CDC definition","healthyVolunteers":false,"sex":"FEMALE","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Primary Event (Acute Hematologic or GI Toxicity)","description":"Acute grade \\>= 3 neutropenia or clinically significant \\>=2 diarrhea or any grade \\>=3 GI toxicity","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"55","spread":null},{"groupId":"OG001","value":"46","spread":null}]}]}]},{"type":"SECONDARY","title":"Progression-free Survival","description":"Time from registration to first recurrence of disease or death from any cause","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"46","spread":null},{"groupId":"OG001","value":"55","spread":null}]}]}]},{"type":"SECONDARY","title":"Acute Adverse Events","description":"Acute grade 2 and 3 Adverse Events occurring Up to 30 days post-treatment","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"17","spread":null},{"groupId":"OG001","value":"17","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"17","spread":null},{"groupId":"OG001","value":"25","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":55},"commonTop":["Grade 3 or higher neutropenia","Grade 3 or higher hematologic toxicity","Clinically significant GI toxicity","Grade 2 GI toxicity","Grade 3 or higher GI toxicity"]}}}